Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00910455 · ClinicalTrials.gov registry record · Phase 1
Study of SRX246 Capsules in Healthy Adult Volunteers
A Phase 1 study, sponsored by Azevan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT00910455: Completed Phase 1 study, sponsored by Azevan Pharmaceuticals.
NCT00910455 is a Phase 1 study that has completed, run by Azevan Pharmaceuticals. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00910455, a Phase 1 study, has completed, sponsored by Azevan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
This is the first study of SRX246 in humans, and is being conducted to begin to establish a safety profile of orally administered SRX246.
Interventions
- DRUG Placebo
- DRUG SRX246
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2009-05 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00910455
The ClinicalTrials.gov registry entry for NCT00910455 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Azevan Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00910455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00910455 about?
NCT00910455 is a clinical study titled "Study of SRX246 Capsules in Healthy Adult Volunteers". This is the first study of SRX246 in humans, and is being conducted to begin to establish a safety profile of orally administered SRX246.
What is the current status of trial NCT00910455?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2009-05. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00910455?
The interventions under investigation include: Placebo (DRUG), SRX246 (DRUG).
Who is sponsoring clinical trial NCT00910455?
This trial is sponsored by Azevan Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.